EU regulator reviews AstraZeneca vaccine again

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S.

The world awaits a decision from Europe’s top medical regulator into whether there is any evidence to show the AstraZeneca coronavirus vaccine is linked to a small number of blood clots reported in people across the continent.

The European Medicines Agency’s expert committee is set to announce the results of its investigation later on Thursday.

Earlier this week, more than a dozen countries including Germany, France, Spain and Italy suspended immunization using the AstraZeneca COVID-19 vaccine after reports of unusual blood clots in several people among the 17 million who have received at least one dose in Europe. Both the EMA and the World Health Organization have said there is no current evidence to suggest the vaccine was responsible and that the benefits of immunization far outweighed the potentially small risk of getting vaccinated.

AstraZeneca said after a careful review of its COVID-19 immunization data, it found no evidence of any increased risk of blood clots in any age group or gender in any country.

Was it worth reading? Let us know.